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Purpose. To determine the impact of secondary procedures performed to maintain arteriovenous fistula (AVF) and arte-
riovenous graft (AVG) patency.
Methods. There hundred and eighty six vascular access procedures were retrospectively evaluated. 156 (40.4%) patients
required radiological interventions to treat acute thrombosis, swelling of the extremity with the access site, insufficient
hemodialysis, or stenosis at an anastomotic site.
Results. The 386 cases comprised 106 AVGs and 280 AVFs. In 138 of the 156 cases, which required a radiological inter-
vention, the treatment was successful and saved the vascular access site. The unassisted post-intervention patency time for
these 138 successful cases was 13.112 months (range, 1e65 months). Twenty-nine (63%) of the 46 access sites treated
with surgical thrombectomy were saved.
Conclusions. Frequent, regular follow-up of hemodialysis patients with vascular access sites is the best way to diagnose
problems early and allow the best chance of long-term function.
Keywords: Hemodialysis; Therapeutic thrombolysis; Thrombectomy; Arteriovenous fistula.Introduction
Vascular access for hemodialysis is one of the defini-
tive surgical solutions for patients with end-stage
renal disease (ESRD) who are not suitable for
peritoneal dialysis. Approximately 300 000 patients
in the United States are currently on long-term hemo-
dialysis.1 In Turkey, roughly 23 000 patients are on
a regular hemodialysis program and the cost of this
care has significant economic impact.2 Maintaining
uninterrupted hemodialysis access is of paramount
importance for reducing patient morbidity and mini-
mizing treatment costs.
According to the 1997 National Kidney Foundation
Dialysis Outcomes Quality Initiative Clinical Practice
(DOQI) guidelines, 50% of patients on hemodialysis
should receive this treatment via an arteriovenous fis-
tula (AVF) rather than an arteriovenous graft (AVG) or
a permanent central catheter.3 These guidelines also
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tula’’ as the primary solution for improving quality
of life andoutcome for patientswith ESRD.Most hemo-
dialysis patients who have autogenous or prosthetic
vascular access sites require secondary procedures to
resolve problems that arise over time. Spontaneous
thrombosis, development of flow-reducing stenosis in
the afferent artery or efferent vein, central vein stenosis,
and central vein occlusion are the most common rea-
sons for re-intervention. In addition to surgical treat-
ment, it is now routine for vascular access stenosis
and thrombosis to be treated with interventional radi-
ology techniques. These include dilatation of a stenotic
segment via either angioplasty or stenting and many
declotting methods.4
The aim of this study was to determine the impact
of secondary procedures that were used to maintain
AVF and AVG patency.
Methods
Between January 1996 and January 2005, 1315 proce-
dures for creating hemodialysis access sites wererved.
702 F. Karakayali et al.performed in Baskent University, Department of Sur-
gery, Ankara, Turkey. We reviewed the findings for
482 of these AVFs and AVGs in 321 patients who con-
tinued to undergo hemodialysis in our units and were
monitored with routine follow-up. Ninety-six of these
482 fistula and grafts never matured, so these were ex-
cluded and data for the remaining 386 AVF and AVG
were retrospectively evaluated. A database was cre-
ated from operative logs and radiology, nephrology,
general surgery and dialysis center records. The de-
mographic data collected were sex and age of patient,
history of dialysis catheter placement, number of
prior fistula created, cause of ESRD, preoperative
venous imaging status and comorbid conditions
(Table 1). In each case, preoperative assessment en-
tailed either physical examination alone or physical
examination plus duplex US scanning and venogra-
phy. Physical examination was the only modality
used to determine the type and site of vascular access
until 1998. We subsequently used preoperative ultra-
sonography and venography in selected patients after
considering their history of prior vascular access oper-
ations and central vein catheterizations. Since 2002,
however, we have used Doppler ultrasonography
and venography to evaluate all patients (except those
without adequate insurance coverage). The most suit-
able vein was selected based on this assessment.
When insufficient AVF or AVG flow for hemodial-
ysis was detected, the first investigative step in each
case was fistulography. For this, the efferent vein of
the fistula was cannulated and a sphygmomanometer
cuff was placed around the arm and inflated to above
systolic pressure. Then contrast medium was injected
and the pressure in the cuff caused reflux of contrast
medium back through the anastomosis site. If the
Table 1. Demographic data and comorbid conditions in 386 hemo-
dialysis cases
Number of AVFs 280
Number of AVGs 106
Sex (M/F) 214/172
Age (mean years) 49.6 15.2
Etiology of ESRD
Diabetes (n) (%) 128 (33.1%)
Hypertension (n) (%) 68 (17.6%)
Glomerulonephritis (n) (%) 55 (14.2%)
Infection (n) (%) 33 (8.5%)
Polycystic kidney disease (n) (%) 21 (5.4%)
Postrenal obstruction (n) (%) 31 (8%)
Amyloidosis (n) (%) 14 (3.6%)
Unknown (n) (%) 36 (9.4%)
Mean duration of ESRD (months) 34.5 38.3
Number of prior dialysis catheters placed 2.9 2.8
Number of previous dialysis access sites 2.7 1.9
Number of patients with PVI 234
PVI: preoperative vascular imaging.Eur J Vasc Endovasc Surg Vol 32, December 2006clinical problem was high venous pressure during
dialysis or swelling of the limb with the access site,
conventional x-ray venography was done to obtain
images of the more proximal veins. If stenosis (de-
fined as >50% reduction in luminal diameter) without
thrombosis was detected in the region of the venous
anastomosis or anywhere along the draining vein or
the central veins, then percutaneous transluminal an-
gioplasty (PTA) was the treatment of choice. In such
cases, the success of the procedure was always
checked with control fistulography and pressure mea-
surements. Stents were placed to prevent elastic recoil
after PTA in cases of suboptimal angioplasty (defined
as >50% narrowing with persistent filling of the ve-
nous collaterals), and in cases where stenosis recurred
within 2 months of successful angioplasty. PTA or
PTA/stent placement was considered technically suc-
cessful if there was <30% residual stenosis and no fill-
ing of the venous collaterals.
In the initial years of our study period (before
2000), thrombosis affecting an AVF or AVG was
treated with early surgical thrombectomy. This prob-
lem was suspected based on loss of thrill at the fistula
site, and each diagnosis was confirmed with Doppler
US prior to operating. Surgical thrombectomy was
performed in the operating room under local anesthe-
sia. If the thrill was restored during the operation and
control Doppler US examination indicated sufficient
flow, the procedure was considered successful.
In subsequent years, in cases where it was appro-
priate we corrected AVF or AVG thrombosis with
pharmaco-mechanical thrombolysis (Fig. 1). In such
instances, the diagnosis was confirmed with Doppler
US and the exact location and extent of the thrombus
was determined by fistulography. Then thrombec-
tomy was performed using the Arrow-Trerotola me-
chanical thrombectomy device (Arrow International
Inc, Middletown, PA, USA) and 2000e3000 IU hepa-
rin was administered during this procedure. In addi-
tion, pulse-spray streptokinase treatment (total dose
150 000e350 000 IU) was administered to every pa-
tient. In 5 cases, balloon mechanical thrombectomy
was also performed. After each percutaneous throm-
bectomy procedure, the patency of the fistula was
evaluated with control fistulography. As well, in
each case where there was a stenotic segment at the
level of the anastomosis, PTA was performed with
a 5e8 mm diameter balloon catheter. In the 2 cases
in which dilatation with high-atmospheric-pressure
balloon catheters (Blue Max, Boston Scientific Corpo-
ration, Watertown, MA, USA) failed (pressure gradi-
ent still higher than 10 mmHg or still >50% stenosis
after the procedure), metallic stents (Palmaz stent,
Cordis Corporation, a Johnson & Johnson company;
703Interventions on Patency of Vascular AccessFig. 1. A thrombosed AVG in the left femoral region of a 64-year-old patient on chronic hemodialysis. The fistulogram
shows massive thrombosis in the graft and a long stenotic segment in the left external iliac vein (a). The graft was recan-
alized by mechanical thrombolysis using an Arrow-Trerotola thrombolytic device followed by a pulse spray thrombolysis
(b), and then a stent was placed in the stenotic segment of the iliac vein (c).Warren, NJ, USA) were placed in the segments
thought to be the main origin of the thrombus.
In cases where acute central vein thrombosis was
impairing AVF or AVG function, catheter-directed
thrombolysis with streptokinase (total dose 150,000e
350,000 IU) was performed. Once percutaneous
thrombolysis was carried out, fistulography was per-
formed to assess for residual thrombosis and stenosis
at the access site. Residual stenosis was corrected by
PTA. If there was elastic (post-procedure) stenosis in
the central vein, and if this blockage was >50%
and/or the pressure gradient was still high, then
a stent (Wallstent, Boston Scientific, Natick, MA,
USA) was placed to address these problems (Fig. 2).
In all cases where an AVF or AVG problem arose,
a central jugular catheter (or a subclavian or femoral
catheter if appropriate) was also inserted for hemodi-
alysis and the patient completed at least 2 hemodialy-
sis sessions with this double-lumen catheter in place.
Radiological or surgical interventions were deemedsuccessful if the access site was sufficient for at least
4 hemodialysis sessions.
Unassisted post-intervention patency time was de-
fined as the interval from a surgical or endovascular
intervention to 1) the time of subsequent access site
thrombosis or 2) the time of final patency assessment
for the study.
Statistical analysis
Mean (SD) was the descriptive statistic used to ex-
press results for quantitative variables. Kaplan-Meier
survival analysis and log-rank statistics were per-
formed according to unassisted post-intervention pa-
tency in different groupings of patients, and rates
for the different patency categories were calculated
at 6 and 12 months after AVF/AVG creation. Differ-
ences between groups for a given parameter were as-
sessed using the Fisher’s exact test or Chi-square testEur J Vasc Endovasc Surg Vol 32, December 2006
704 F. Karakayali et al.Fig. 2. A fistulogram of the left upper extremity of a 52-year-old hemodialysis patient with fistula dysfunction shows severe
stenosis of the left brachiocephalic vein (a). The results of balloon dilatation were suboptimal (b, c). A 14 40-mm self-
expanding stent (Wallstent) was deployed, and this resulted in good filling of the vein (d).with Yates correction, as appropriate. All statistical
analyses were performed using the statistical software
package SPSS for Windows, version 11.0.
Results
Demographic data
The 386 patients in the study were 57% men and 43%
women. The mean age was 49.6 15.2 years (range,
19e80 years), the mean duration of ESRD was
34.5 38.3 months (range, 1e170 months), the mean
number of previous central vein dialysis catheter
placements was 2.9 2.8 (range, 0e14), and the
mean number of previous hemodialysis access sites
was 2.7 1.9 (range, 1e11). The causes of ESRD
were diabetes (128 cases, 33.2%), hypertension (68
cases, 17.6%), glomerulonephritis (55 cases, 14.2%),
infection (33 cases, 8.5%), postrenal obstruction (31
cases, 8%), polycystic kidney disease (21 cases,Eur J Vasc Endovasc Surg Vol 32, December 20065.4%), amyloidosis (14 cases, 3.6%), and unknown
(36 cases, 9.3%) (Table 1).
The 386 cases comprised 106 (27.5%) AVGs and 280
(72.5%) AVFs. The different types of vascular accesses
created were snuffbox (43 cases), radiocephalic
(Brescia-Cimino, 86 cases), antecubital brachiocephalic
(103 cases), brachioaxillary (51 AVGs), brachiobasilic
(31AVGs), femorofemoral (24AVGs), basilic vein trans-
positions (45 cases), femoral vein superficializations
(2 cases), and brachial vein superficialization (1 case).
Postoperative radiological interventions
During follow-up, 156 (40.4%) of the 386 cases required
radiological interventions due to acute thrombosis,
swelling of the extremity with the access site, insuffi-
cient hemodialysis, or stenosis at an anastomosis site.
Of the 156 cases with complications that required
radiological intervention, 47 were acute thrombosis
(treated with pharmaco-mechanical thrombolysis)
and 109were stenosis (treatedwith other percutaneous
705Interventions on Patency of Vascular Accessprocedures). In 138 (88.5%) of these cases, the interven-
tion was successful and saved the vascular access site.
The unassisted post-intervention patency time for
these 138 cases was 13.1 12 months (range, 1e65
months) and the rates of unassisted post-intervention
patency at 6 and 12 months were 78% and 45%,
respectively.
Of the 47 total pharmaco-mechanical thrombolysis
procedures performed, 39 (82.9%) were successful.
In 31 of these 39 cases (14 upper-arm AVGs, 9 femoro-
femoral AVGs and 4 Brescia-Cimino AVFs, 4 brachio-
cephalic AVFs), acute thrombosis was initially
diagnosed based on clinical findings, confirmed with
imaging studies, and then treated with thrombolytic
agents and angioplasty. The other 8 successfully
treated cases of acute thrombosis were in the central
veins and all of them were subclavian vein thrombo-
sis. Four of these cases were managed with thrombo-
lytic therapy and angioplasty, and the other 4 required
additional stent placement.
Of the 109 other types of percutaneous radiological
interventions that were performed, 99 (90.8%) were
successful. In all 109 of these cases, fistulography
showed stenosis at the anastomosis site or central
vein stenosis. Eighty of these stenosis were in the cen-
tral veins. Two cases of brachiocephalic vein stenosis,
31 cases of subclavian vein stenosis, and 2 cases of
iliac vein stenosis were treated with angioplasty
alone. Ten other cases of brachiocephalic vein steno-
sis, 25 other cases of subclavian vein stenosis, and
10 other cases of iliac vein stenosis required additional
stent placement after angioplasty. The other 19 percu-
taneous interventions were angioplasty at the venous
portion of the anastomosis in 10 AVFs, stent place-
ment in 5 AVGs, and angioplasty at the efferent vein
in 4 cases (2 cephalic veins, 2 axillary veins). The 10
failed percutaneous interventions were in 4 patients
with AVF stenosis, 2 with AVG stenosis, 3 with subcla-
vian vein stenosis, and 1 with brachiocephalic vein
stenosis.
Surgical thrombectomy
In addition to the 47 acute thrombosis cases that were
treated with pharmaco-mechanical thrombolysis, an-
other 46 cases of acute thrombosis (17 AVGs and 29
AVFs) were managed with surgical thrombectomy.
The demographic characteristics of patients with
acute thrombosis were similar in both thrombolysis
and thrombectomy groups. Twenty-nine of these 46
access sites (14 AVGs, 15 AVFs) were saved by surgi-
cal thrombectomy. For these 29 cases, the rates of un-
assisted post-intervention patency at 6 and 12 monthswere 34% and 7%, respectively. The corresponding
rates for the 31 cases of AVF or AVG thrombosis
that were successfully treated with percutaneous
pharmaco-mechanical thrombolysis were 52% and
15%. Although both rates were higher in the percuta-
neously treated group, the differences were not statis-
tically significant ( p> 0.05 for both) (Table 2).
The abovementioned 29 cases rescued with surgical
thrombectomy were further analyzed according to
access type. The rates of unassisted post-intervention
patency for the AVFs in this subgroup at 6 and 12
months were 52% and 15%, respectively. The corre-
sponding values for the AVFs successfully treated
with percutaneous pharmaco-mechanical thromboly-
sis were 22% and 13%. The differences between these
corresponding rates were not statistically significant
( p> 0.05 for both) (Table 2). For the AVGs successfully
treated with surgical thrombectomy, the rates of unas-
sisted post-intervention patency at 6 and 12 months
were 43% and 7%, respectively. The corresponding
values for the AVGs successfully treated with percuta-
neous pharmaco-mechanical thrombolysis were 63%
and 16%. The differences between these correspond-
ing rates were not statistically significant ( p> 0.05
for both) (Table 2) (Fig. 3).
Discussion
Turkish Nephrology Society data from 2003 indicate
that, in 72.5% of the cases of AVF or AVG thrombosis
in that year, the solution was to create a new access
site.2 However, when such a problem develops,
many of these sites can be saved with closer patient
follow-up and prompt surgical or radiological inter-
vention. This interventional approach also maintains
patients’ quality of life and reduces morbidity and
treatment costs.
Aside from surgical methods, today it is routine to
use interventional radiology techniques to treat steno-
sis and thrombosis of hemodialysis vascular access
sites or central veins. These alternatives include dila-
tation of stenotic segments with or without stent
placement, and many declotting techniques. In series
published on percutaneous treatment of thrombosed
AVF and AVGs, stenosis was the underlying cause
in almost 85% of cases.3,4 Stenosis of vascular access
for hemodialysis is usually caused by proliferation
of intimal smooth muscle cells in the region of the
venous anastomosis. However, this problem can occur
anywhere along the draining vein.5 Four of the pa-
tients in our series had efferent vein stenosis in axil-
lary and cephalic veins, and we were able to rescue
all 4 of these access sites with PTA.Eur J Vasc Endovasc Surg Vol 32, December 2006
706 F. Karakayali et al.Table 2. Comparison of 6- and 12-month unassisted post-interventional patency rates for surgical and percutaneous treatment of throm-
bosis, with patients categorized according to fistula type
Surgical treatment 6 mo (upip) 12 mo (upip) Percutaneous
treatment
6 mo (upip) 12 mo (upip) P
AVFþAVG n:29 34% 7% AVFþAVG n:31 52% 15% p> 0.05 for both
AVF n:15 52% 15% AVF n:8 22% 13% p> 0.05 for both
AVG n:14 43% 7% AVG n:23 63% 16% p> 0.05 for both
upip: unassisted post-intervention patency.
AVG: arteriovenous graft.
AVF: arteriovenous fistula.p=0.5815
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Fig. 3. Kaplan-Meyer analysis and log-rank statistics for 6-
month unassisted post-interventional patency rates for sur-
gical and percutaneous treatment of AVF (a) and AVG (b)
thrombosis.Eur J Vasc Endovasc Surg Vol 32, December 2006DOQI guidelines recommend that AVFs should be
created in at least 50% of all patients who are newly
diagnosed with ESRD.3 However, data from the Turk-
ish Nephrology Society Registry reveal that, in our
country, double-lumen central venous catheters are
preferred for initial vascular access in 62.2% of all he-
modialysis patients.2 In most cases, evaluation for
a permanent access site is done after initial access
has been secured. Complications with vascular access
are also common indications for temporary central
venous catheterization. Unfortunately, the subclavian
vein is the preferred site for central venous catheter
insertion, and stenosis or thrombosis of this vessel
develops in 42% to 50% of these cases.6,7 Such prob-
lems may not become clinically apparent until venous
flow is increased, resulting in swelling of the upper
limb. Similarly, internal jugular catheter placement
can cause damage to the brachiocephalic vein and
femoral catheterization can damage the iliac vein.5
In some cases, stenosis or occlusion of the venous out-
flow of an AVF occurs in the absence of previous cath-
eterization.8 Stenosis of central veins usually causes
venous hypertension, which is commonly associated
with chronic pain, edema in the affected extremity,
and high venous pressure during dialysis.
Blood flow in a stenotic or occluded central vein
can be restored and maintained with surgical proce-
dures or endovascular techniques. Surgical treatment
of central vein stenosis requires thoracotomy, but the
patency rates recorded with this method have not
been significantly better than those recorded for endo-
vascular techniques.9,10 Today, percutaneous translu-
minal methods, including PTA and stent placement,
are gaining popularity as therapeutic alternatives to
open surgery. Endovascular approaches can be done
under local anesthesia, are well tolerated by the
patient, and require shorter hospitalization time than
surgery.11 Central vein stenosis or occlusion that af-
fects an upper extremity can be treated with balloon
angioplasty alone. However, because of the high inci-
dence of elastic recoil, patients in whom PTA fails and
those with extensive stenosis and lesions that recur
after multiple PTA procedures are usually treated
707Interventions on Patency of Vascular Accesswith stent placement.12e14 After stent placement, mul-
tiple re-interventions are often needed to prolong pa-
tency. Re-stenosis can be treated with angioplasty
alone in most cases, but sometimes additional stent
placement is required. Reported rates of assisted
primary patency at 1 year range from 33% to 97%.14,15
In our series, 84 of the 109 cases of venous stenosis
were in central veins. In other words, 84 (22%) of the
386 total access sites in the study developed central
vein stenosis. This high rate may be a reflection of the
high frequency of dialysis catheter placement for secur-
ing initial access, as noted in the registry information
above. Each of our 84 patientswith central vein stenosis
exhibited insufficient flow for hemodialysis and/or
venous hypertension. All these cases were treated
with percutaneous interventions, and stents were
placed when necessary. The success rate was 95%.
In most patients who develop acute thrombosis of
a central vein, the underlying pathology is venous sta-
sis.When there is acute central vein occlusion related to
dialysis access, stent deployment is very effective as
a first step. This method has long been recommended
as the primary treatment tool, and offers better long-
term patency than other therapeutic modalities, such
as percutaneous balloon angioplasty alone.16 Mechani-
cal thrombectomy is not recommended as routine
primary treatment for dialysis-related central vein
occlusion because of sharp angles in the vasculature
and thin vessel walls. On the other hand, thrombecto-
my devices are effective tools for debulking neointimal
tissue in cases of stent reocclusion.16,17 Catheter-
directed thrombolysis is associated with high rates of
lysis because the thrombolytic agent is delivered di-
rectly to the site in high concentrations. Some authors
have reported good results with a combination of
thrombolytic agents, angioplasty and stent place-
ment.18 In all patients our protocol for treating acute
thrombosis in a central vein is percutaneous thrombo-
lytic treatment with additional PTA and stenting
when necessary. In some of our hemodialysis patients,
central vein stenosis developed but treatment was not
attempted because there was less than 50% blockage.
In 15 of these cases, thrombosis developed in addition
to (and likely due to) the stenosis. All these patients
were successfully managed with a combination of
thrombolytic therapy and PTA, and some required ad-
ditional stent placement.
When a vascular access provides inadequate flow
for dialysis, the problem is usually stenosis of the
vein adjacent to the anastomosis site in an AVF, or ste-
nosis of the venous anastomosis region in an AVG. Al-
though balloon angioplasty can widen the lumen and
restore flow at least temporarily, elastic recoil is
common and the stenotic segment may resist evenhigh-pressure dilatation.5 Excellent technical success
has been documented with PTA for dysfunctional
AVGs and AVFs.12e19 Repeat angioplasty can be per-
formed if stenosis of an AVF or AVG recurs, and the
success rates are similar to the first angioplasty at-
tempt.12 It has been clpaimed that, in cases of recurrent
venous stenosis at an access site, angioplasty plus stent
placement results in longer intervals between interven-
tions than angioplasty alone.20 Recently, Beathard
studied patients who had stenosis at the venous
anastomosis of AVGs and compared results with PTA
alone to results with PTA combined with placement
of self-expanding stents.21 The data indicated that
stenting provided no additional benefit. In our series,
21 patients had stenosis in the anastomosis region of
an AVF or AVG. Percutaneous radiological interven-
tions were successful in 15 of these cases (71% success
rate). Five of these stenotic segmentswere at the venous
anastomosis site of an AVG and were managed with
PTA and stent placement. The other 10 were AVFs,
and PTA alone was sufficient for dilatation in these
cases.
We also determined the unassisted post-interventional
patency time for each case of occlusion/stenosis of
a central vein, AVF or AVG that was treated with
percutaneous radiological interventions. For these
cases, the rates of unassisted post-interventional pa-
tency at 6 and 12 months were 78% and 45%, respec-
tively. These figures are both higher than the targets
recommended by the DOQI (50% and 40%,
respectively).3
Thrombosis of an AVF or AVG is a frequent prob-
lem that leads to significant morbidity and longer hos-
pital stays for the dialysis patient.22 In the past,
thrombosis of a dialysis shunt was almost always cor-
rected with surgical thrombectomy. Today, there are
also numerous percutaneous treatment alternatives
for thrombosed AVFs and AVGs. These include
mechanical thrombectomy, pharmaco-mechanical
thrombolysis, and percutaneous infusion of pharma-
cological agents for thrombolysis.23 The National
Kidney Foundation’s clinical practice guidelines for
vascular access state that each institution should
choose the most appropriate approach for resolving
access-site thrombosis based on the expertise at that
particular center. In general, treatment of AVG throm-
bosis is thought to be more successful than treatment
of AVF thrombosis.3 In our study, there was only 1
unsuccessful pharmaco-mechanical thrombolysis at-
tempt in AVFs (success rate 87.5%) and we had
100% success with this technique in AVGs. The corre-
sponding success rates with surgical thrombectomy
were 51.7% for AVFs and 82.3% for AVGs. DOQI
guideline No. 21 states that immediate patency rateEur J Vasc Endovasc Surg Vol 32, December 2006
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but we were only able to reach this target in the group
that underwent percutaneous treatment. In addition
to higher success rates for percutaneous treatment of
AVFs and AVGs, we found that the chance of rescue
with surgical thrombectomy was higher if the vascu-
lar access was an AVG. The overall rescue rate with
percutaneous pharmaco-mechanical thrombolytic
treatment was 88.5%, whereas the corresponding
rate for the surgical procedures was 63%. Overbosch
et al. examined the cases of 24 patients with occluded
Brescia-Cimino AVFs, and noted that 20 (83%) were
successfully declotted with a Hydrolyser thrombec-
tomy catheter (Cordis Corporation, USA).24 The me-
dian assisted patency time for these AVFs was 34
weeks, which was significantly shorter than that for
the occluded AVGs in the study.
Sands et al. observed no significant differences be-
tween surgical and percutaneous treatment of AVG
thrombosis with respect to success rates, primary pa-
tency times, or complication rates in a retrospective
study.25 Beathard described equal initial success rates
when mechanical thrombolysis was compared with
surgical thrombectomy in AVGs.26
Green et al. reported higher rate of patency in favor
of the surgical treatment group in a multicenter trial.27
In our series, the 6- and 12-month rates of unassisted
primary patency were higher for the AVGs that were
treated percutaneously than for the AVGs that were
treated surgically. DOQI guideline No. 21 recom-
mends that, for AVGs treated with percutaneous
thrombolysis and PTA combined, the unassisted pa-
tency rate at 3 months should be 40% or higher.3
The same guideline notes that, for AVGs treated
with surgical thrombectomy, this rate should be 50%
at 6 months and 40% at 12 months. According to
our data, we reached the abovementioned target un-
assisted patency rate for percutaneous treatment of
AVG thrombosis (our rate: 63% at 6 months). Our
unassisted patency rate for AVGs at 6 months after
surgical thrombectomy was relatively close to the rec-
ommended level (our rate: 43%), but our rate at 12
months (7%) was significantly below target. Green
et al.27 reported a significantly higher technical failure
rate in their endovascular treatment group, they also
found that the failure rate for surgically treated
AVFs was particularly high. Trerotola et al. used the
Arrow-Trerotola percutaneous device to treat throm-
bosed AVGs and recorded 95% technical success and
39% primary patency at 3 months.28
AVF thrombosis is a less frequent clinical problem
than AVG thrombosis. In general, the percutaneous
declotting techniques that have recently been vali-
dated in AVGs are more difficult to perform inEur J Vasc Endovasc Surg Vol 32, December 2006AVFs. As well, few published articles have dealt with
this issue and the patient numbers presented are
relatively small. The findings in many reports19,23,24
suggest that percutaneous interventions for occluded
AVFs are at least as effective as surgical treatment
with respect to technical success and patency times.
In our series, the technical failure rate for pharmaco-
mechanical thrombolytic treatment plus PTA (2 failed
cases, 20%) was lower than the failure rate for surgical
thrombectomy (51%). However, the rate of unassisted
primary patency at 6 months was more than 2 times
higher in the surgical thrombectomy group (52%). We
found that, for both the AVFs and AVGs, in the long
term the surgical procedures extended mean patency
times to a somewhat greater extent than the percutane-
ous techniques. However, the differences were not
statistically significant because the patient numbers
were small.Over the long term,neither thepercutaneous
nor the surgical techniques yielded optimal outcomes.
Frequent follow-up of hemodialysis patients with
vascular access sites is the best way to diagnose prob-
lems early. This allows the best chance of rescuing
a site rather than creating a new one. The rescue
approach reduces morbidity and decreases the cost
of hemodialysis treatment.
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